GC 4419

Drug Profile

GC 4419

Alternative Names: GC-4419

Latest Information Update: 03 Oct 2016

Price : $50

At a glance

  • Originator Galera Therapeutics
  • Class Antifibrotics; Antineoplastics; Chemoprotectants; Small molecules
  • Mechanism of Action Antioxidants; Superoxide dismutase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stomatitis
  • Phase I Head and neck cancer
  • No development reported Cancer; Fibrosis

Most Recent Events

  • 10 Apr 2017 Galera Therapeutics plans a phase I GTO-003 trial of GC 4419 in comparision with GC 4711 in Healthy Volunteers in Australia (NCT03099824)
  • 01 Aug 2016 Galera Therapeutics completes a phase I trial for Head and neck cancer (First-line therapy) in USA (NCT01921426)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top